Vanderbilt-Ingram Cancer Center has earned a Merit Extension Award from the National Cancer Institute in recognition of more than a decade of sustained exceptional progress.
Blane Hollingsworth became the first patient at Vanderbilt to undergo a liver transplant under the protocol for cholangiocarcinoma, or bile duct cancer.
A Vanderbilt study found that a drug that has been used for decades for intestinal pinworms, can be repurposed as a preventative treatment for stomach cancer.
Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
Cancer at the age of 13 forced him to give up his dream of professional football. While undergoing treatment, he found a new dream.
A Vanderbilt study found that a molecular signature that predicts aggressive thyroid cancer could help guide treatment approaches for patients.
Accessibility Tools